ChemoCentryx (NASDAQ: CCXI)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
ChemoCentryx Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ChemoCentryx Company Info
Chemocentryx Inc. is a biopharmaceutical company focused on discovering developing and commercializing orally-administered therapeutics to treat autoimmune diseases inflammatory disorders and cancer.
News & Analysis
The rare-disease specialist is being bought out at a sizable premium.
Years from now you could be thanking yourself for buying shares of these two companies today.
A long, drawn out regulatory review weighed on the drugmaker's shares last year.
The stock surged after obtaining FDA approval for avacopan.
Investors are excited about the biotech's game-changing new drug.
The broader market was mixed on Friday.
They've been struggling thus far in 2021, but things could turn around quickly for these companies.
Analysts following this risky biotech stock have changed their tune.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/26/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
CCXI earnings call for the period ending September 30, 2021.
CCXI earnings call for the period ending June 30, 2021.
CCXI earnings call for the period ending March 31, 2021.
CCXI earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.